The week of June 29 june to 03 july was quiet due to days off on the Canadian and American stock markets but some news caught the eye.
M2Bio Sciences, Inc | WUHN
M2Bio Sciences inc (formerly Wuhan General group) once again surprised investors with important news that allows the company to take a huge step forward.
M2Bio Sciences inc announce, that effective June 30th, 2020, it has signed a letter of intention to pursue a Partnership where Jugular will support and offer its expertise to the Company in creating a specialized division within MJ Medtech that focuses on marketable innovation within the functional foods sector.
Companies plan to develop and manufacturer CBD Functional Foods immediately under the Dr. AnnaRx brand:
Immune Booster Shot
Energy Booster Shot
Relax and Unwind Shot
“Jugular own multiple functional food brands that are sold throughout Europe and distributed Internationally.“
M2Bio Sciences Inc. begins to open the eyes of investors with huge potential, a thin float of 10 million and a market value far from its peers
“M2Bio Sciences, Inc. is currently in Pre-enrolment Patient- screening for Phase 1 Human trial“
Visit M2Bio Sciences profile | HERE
Revive Therapeutics | RVV
Revive Therapeutics | RVV has taken another huge step forward this week with a story that may completely change its history.
Revive Therapeutics announce it has submitted today its Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“U.S. FDA”) for a Phase 3 confirmatory study for Bucillamine as a potential treatment in COVID-19.
“We are very pleased in achieving this major milestone of filing our IND for a Phase 3 confirmatory study to evaluate Bucillamine in the treatment of patients with mild-moderate COVID-19, which was based on the recommendation from the US FDA from our pre- IND meeting earlier this year, “
“We are preparing plans for initiating the Phase 3 study upon the IND becoming active by the U.S. FDA and we look forward to advancing Bucillamine as a potential new treatment option for patients with a confirmed diagnosis of COVID-19 globally.”
-said Michael Frank, Revive’s Chief Executive Officer.
Following the halted before the announcement of this news, the action on the American side (OTC) exploded with an increase of more than 130% during the day.
Visit Revive Therapeutics profile | HERE
Champignon Brands Inc | SHRM
Since June 19, Champignon Brands Inc. has been served a Cease Trade Order (CTO) by the British Columbia Securities Commission.
“SHRM is halted indefinitely until Champignon files missing business acquisition reports“
The Order was issued due to Champignon’s failure to file Business Acquisition Reports (Form 51-102F4) for three significant acquisitions | Artisan Growers Ltd. | Novo Formulations Ltd. | Tassili Life Sciences Corp.
The Company will fully cooperate with the Commission, to assist in completion of the review and revocation of the cease trade order in a timely fashion.
M2Bio Sciences inc, an opportunity of a lifetime?| LOOK HERE
For more information on the psychedelics market and all the companies involved | HERE
Sign up for MORE news updates !
This article is written and published by The Cannabis Stock
Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies
The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.
Disclosure : Wuhan General group inc and Revive Therapeutics are clients of The Cannabis Stock.